273 related articles for article (PubMed ID: 26071672)
1. Coagulation activation after discontinuation of VTE treatment with different oral anticoagulants and impact on 12-month clinical outcomes.
Beyer-Westendorf J; Gehrisch S; Stange T; Tittl L; Siegert G; Weiss N
Thromb Res; 2015 Aug; 136(2):261-6. PubMed ID: 26071672
[TBL] [Abstract][Full Text] [Related]
2. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
[TBL] [Abstract][Full Text] [Related]
3. Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis.
Barrett YC; Wang J; Knabb R; Mohan P
Thromb Haemost; 2011 Jan; 105(1):181-9. PubMed ID: 20941459
[TBL] [Abstract][Full Text] [Related]
4. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
Hillis C; Crowther MA
Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
[TBL] [Abstract][Full Text] [Related]
5. Risk of recurrent venous thromboembolism after discontinuation of vitamin K antagonist treatment: a nested case-control study.
Martinez C; Katholing A; Folkerts K; Cohen AT
J Thromb Haemost; 2016 Jul; 14(7):1374-83. PubMed ID: 27079164
[TBL] [Abstract][Full Text] [Related]
6. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review.
Wu C; Alotaibi GS; Alsaleh K; Sean McMurtry M
Thromb Res; 2014 Sep; 134(3):627-32. PubMed ID: 25047174
[TBL] [Abstract][Full Text] [Related]
7. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.
Douketis J; Tosetto A; Marcucci M; Baglin T; Cushman M; Eichinger S; Palareti G; Poli D; Tait RC; Iorio A
Ann Intern Med; 2010 Oct; 153(8):523-31. PubMed ID: 20956709
[TBL] [Abstract][Full Text] [Related]
8. The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry.
Bauersachs R; Agnelli G; Gitt AK; Monreal M; Mismetti P; Willich SN; Laeis P; Fronk EM; Bramlage P; Cohen AT;
Thromb Res; 2017 Sep; 157():181-188. PubMed ID: 28780343
[TBL] [Abstract][Full Text] [Related]
9. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.
Schulman S; Goldhaber SZ; Kearon C; Kakkar AK; Schellong S; Eriksson H; Hantel S; Feuring M; Kreuzer J
Thromb Haemost; 2015 Jul; 114(1):150-7. PubMed ID: 25739680
[TBL] [Abstract][Full Text] [Related]
10. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
11. Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism.
Bryk AH; Piróg M; Plens K; Undas A
Vascul Pharmacol; 2016 Dec; 87():242-247. PubMed ID: 27865826
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
Prandoni P
Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis.
Sobieraj DM; Coleman CI; Pasupuleti V; Deshpande A; Kaw R; Hernandez AV
Thromb Res; 2015 May; 135(5):888-96. PubMed ID: 25795564
[TBL] [Abstract][Full Text] [Related]
14. D-dimer levels and risk of recurrent venous thromboembolism.
Eichinger S; Minar E; Bialonczyk C; Hirschl M; Quehenberger P; Schneider B; Weltermann A; Wagner O; Kyrle PA
JAMA; 2003 Aug; 290(8):1071-4. PubMed ID: 12941680
[TBL] [Abstract][Full Text] [Related]
15. Persistence to direct oral anticoagulants for acute venous thromboembolism.
Dronkers CEA; Lijfering WM; Teichert M; van der Meer FJM; Klok FA; Cannegieter SC; Huisman MV
Thromb Res; 2018 Jul; 167():135-141. PubMed ID: 29843087
[TBL] [Abstract][Full Text] [Related]
16. Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients.
Kooistra HA; Veeger NJ; Khorsand N; Kluin-Nelemans HC; Meijer K; Piersma-Wichers M
Thromb Haemost; 2015 Apr; 113(4):881-90. PubMed ID: 25518854
[TBL] [Abstract][Full Text] [Related]
17. Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of randomized controlled trials.
Di Minno MN; Lupoli R; Di Minno A; Ambrosino P; Scalera A; Dentali F
Ann Med; 2015 Feb; 47(1):61-8. PubMed ID: 25665582
[TBL] [Abstract][Full Text] [Related]
18. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.
Kearon C; Spencer FA; O'Keeffe D; Parpia S; Schulman S; Baglin T; Stevens SM; Kaatz S; Bauer KA; Douketis JD; Lentz SR; Kessler CM; Moll S; Connors JM; Ginsberg JS; Spadafora L; Julian JA;
Ann Intern Med; 2015 Jan; 162(1):27-34. PubMed ID: 25560712
[TBL] [Abstract][Full Text] [Related]
19. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy.
Zolfaghari S; Harenberg J; Froelich L; Wehling M; Weiss C
Semin Thromb Hemost; 2014 Feb; 40(1):121-8. PubMed ID: 24381153
[TBL] [Abstract][Full Text] [Related]
20. Managing pulmonary embolism from presentation to extended treatment.
Cohen AT; Dobromirski M; Gurwith MM
Thromb Res; 2014 Feb; 133(2):139-48. PubMed ID: 24182642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
